TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.
TGF-beta2 secretion by high grade gliomas has been implicated as one of the major factors contributing to tumor growth, alterations in the host immune response to tumor, and failure of gliomas to respond to current immunotherapy strategies. We hypothesized that targeted delivery and inhibition of TGF-beta2 by TGF-beta2 antisense oligonucleotides (AS-ODNs) would overcome tumor-induced immunosuppression and enhance the capacity of tumor vaccines to eradicate established brain tumors. Utilizing the mRNA sequences of TGF-beta2, specific AS-ODNs were constructed and tested for their ability to inhibit TGF-beta2 production in 9L glioma cells. The effect of combining local intracranial administration of antisense ODNs with systemic tumor vaccine was examined. Fisher 344 rats were vaccinated subcutaneously with irradiated 9L tumor cells 3 days after intracranial tumor implantation. Four days after vaccination, ODNs were administered into the tumor mass and survival was followed. ODNs delivered locally distributed widely within the brain tumor mass and inhibited TGF-beta2 expression. Survival of tumor-bearing rats treated with the combination of local antisense and systemic tumor vaccine was significantly enhanced (mean survival time (MST): 48.0 days). In contrast, MST for animals treated with nonsense plus vaccine, vaccine alone, antisense alone or PBS showed no survival advantage and no statistical differences between groups (33.5 days, 29.0 days, 37.5 days, and 31.5 days, respectively). Our data supports the hypothesis that local administration of antisense TGF-beta2 ODNs combined with systemic vaccination can increase efficacy of immunotherapy and is a novel, potentially clinically applicable, strategy for high-grade glioma treatment.
Liu
Yang
Y
Department of Neurosurgery, C-307, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO, 80262, USA.
Wang
Qing
Q
Kleinschmidt-DeMasters
B K
BK
Franzusoff
Alex
A
Ng
Ka-yun
KY
Lillehei
Kevin O
KO
D000818:Animals; D001932:Brain Neoplasms / Q000401:mortality / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic; D004195:Disease Models, Animal; D005822:Genetic Vectors; D018316:Gliosarcoma / Q000401:mortality / Q000628:therapy*; D047468:Immunoprecipitation; D007167:Immunotherapy / Q000379:methods*; D007279:Injections, Subcutaneous; D008297:Male; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344; D015996:Survival Rate; D053781:Transforming Growth Factor beta2 / Q000037:antagonists & inhibitors*; D014407:Tumor Cells, Cultured; D014611:Vaccination
D019496:Cancer Vaccines; D016376:Oligonucleotides, Antisense; C509041:TGFB2 protein, human; D053781:Transforming Growth Factor beta2